



## Petition

### Reply to Office Action Summary

Applicant: Shin-Jen Shaio

Application No.: 10/554,315

Filed Date: 10-24-2005

Group Art Unit: 1614

Attorney Docket No.:

Examiner: THOMAS, TIMOTHY P

Confirmation No.: 2698

#### To the Commissioner of Patents:

The applicant was notified by a decision in response to the communication, filed May 10, 2010, which is being treated under the provisions of 37 CFR 1.181 (no fee) to withdrawn the holding of abandonment. In which the Office Action Summary was attached. A request for reconsideration of this decision should be filed within two months from the mail date of this decision.

#### In response to the Office Action Summary

##### 1. A general principle of the invention

There are few paragraphs of Examination Guidelines for Patent Applications relating to Medical Inventions in the UKIPO 2008, wherein the second medical use claims- the substance or composition maybe concerning the invention now. In assessing novelty and invention step, in paragraph 145 it says: However, if the specification discloses a general principle capable of general application, a claim in correspondingly general terms may be acceptable. There is no need to show proof of its application in every individual possible instance which could fall within the scope of the claim. This principle is of course, applicable to more than just second medical use claims, but is particularly important for such claims are defined by the purpose of product.

The general principle of the invention is supplying protons in blood by administering edible acid (carboxyl function group being the generic structure, and or phosphoric acid, releasing proton) and lowering the humoral pH by which histamine is inhibited and treats ailments finally. This general principle of the invention is fully supported by the description of present application. This general principle was demonstrated in testing the rate of inhibiting histamine, the main factor of hypersensitivity diseases, in examples of table 2 for testing of histamine inhibition (page 17, [0081] Table-US-00002) using 100% of each compound in each experimentation. There are 1-34 examples. All these acids used have the same property of releasing the same protons, lowering the humoral pH and shown the same results of inhibiting histamine. Accordingly, carboxylic structure or protons releasing structure contained acids are the generic compounds (or derivatives)

which are acceptable by paragraph 145 of Second use medical guidelines, because there are disclosures in the description enabling the skilled person to decide which of other carboxylic acids would have so worked.

In the other words, it is the common principle that all carboxylic acids and phosphoric acid claimed show the same treating properties. No matter what kind of carboxylic acid or phosphoric acid claimed in claims all of them are doing the same simplest reaction of releasing protons, lowering humoral pH and forming protonation between histamine and protons. All the carboxylic acids or phosphoric acid treat the same ailments by the same protons being a general principle of the invention. That is the core principle of the invention. Just as concerning the capability of controlling the activities of histamine, even though in other exemplified embodiments there is some ailments treated only by one kind of carboxylic acids or phosphoric acid in examples, it is also reasonable to consider that other carboxylic acid or phosphoric acid would do the same work of that ailment treatment. That evidence was improved by the facts shown in the examples 4-34 in [0081] Table-US-00002 of the specification, different carboxylic acids or phosphoric acid all shown the same effect in treating allergy ailments which could fall within the scope of the claim. Accordingly, only one carboxylic acid testing for one kind of ailment would apply to other carboxylic acids or phosphoric acid. Therefore, there is no way to elect any more. Also all acid or phosphoric acid species being encompassed in claims were identified according to paragraph 145 of Second use medical guidelines.

Both Examiners of UKIPO and CIPO had allowed the claims which are the same as claimed in USPTO application. In UKIPO the patent is GB2433441 granted on 20 April 2010 and was published in Patent Journal on 19 May 2010.

The applicant suggests courteously that would the Examiner please assessing the support for the invention by a new concept but not by the traditional concept of one compound only for one kind ailment, because the way of disease treatment is completely different from the traditional method. In all biochemical reactions, including diseases, are taking place in a defined pH value, says in a little basic condition of pH 7.4 which could be affected by the addition of protons completely, and inducing a result of ailment treatment. This finding concerns a nature biochemical reaction of disease treatment and completely against the traditional concept of drug treatment. To the best knowledge of the applicant that finding is first found by the applicant and apply to treat diseases.

There is a nature evidence which happens in our body could be applied to support this invention. It is well known that after a hard working of muscles, violent and repeating endure exercise for a long period of time, a large amount of lactic acid is formed in that part of body. Normally, our scientists explain that is the product of the oxidation of glucose in a condition of insufficient of oxygen. But, they did not pay attention to the fact that natural immune and defence of our body. After violent and repeating endure exercise, there were a large amount of dead cells and injured structure of muscles caused in the body. Those dead cells and injured

structure of muscles would be recognized as antigens to our body by immune reaction. In generally condition, a great amount of histamine should be produced and causing bad inflammation in that part by immune reaction. Why not? That is because the lactic acid formed can release protons which show the ability of inhibition of histamine's reactions. To apply this nature alleviation and cure of diseases is the main innovation of this invention.

2. To allow reinstating the description of application, but not claims.

The published description of application which done by the former attorney, Chauncey Johnson, was very rough and poor not only omitting many contents of the application but also done many mistakes in that. This content was not truth, especially, omitting some acids such as succinic acid, acetic acid, phosphoric acid and their acidic salts in Table 2 of section [0081]. So the petitioner courteously asks the Examiner that allows the petitioner to amend as the content filed in PCT.

3. The prior art Ohashi, et al. (US 6,297,244B1) is not concerning the invention.

The referred prior art as its abstract said: A stabilized pharmaceutical composition comprising

(R)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (hereinafter, referred to as "AS-3201") and as a stabilizer at least one acidic substance having an acidity more potent than that of AS-3201, such as ascorbic acid, citric acid, tartaric acid, lactic acid, maleic acid, malic acid or phosphoric acid. Therefore, even though they contain some of acids, they are used as in stabilizing agent for "AS-3201", and do not concerning the invention which lower humoral pH and treat ailments.

4. Amendment by rejoin claims